Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27582027 | 0.81 | CES2 (0.45) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL2800138 | 0.79 | ALOX5 (0.40) | HDAC4HDAC7HDAC5BRD4CACNA2D1 | |
| SCHEMBL2799259 | 0.78 | CACNA2D1 (0.56) | CACNA2D1CACNB2CACNA1C | |
| SCHEMBL2803495 | 0.78 | AOC3 (0.47) | BRD4AOC3ACHE | |
| SCHEMBL2162950 | 0.73 | TSHR (0.57) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL10837272 | 0.73 | CES2 (0.47) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL2198244 | 0.71 | SMN1; SMN2 (0.49) | CACNA2D1CACNB2CACNA1CSLC6A2SLC6A4 | |
| SCHEMBL14088061 | 0.70 | CES2 (0.52) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL213645 | 0.70 | CES2 (0.52) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL508016 | 0.70 | CES2 (0.52) | CES2CES1HDAC4HDAC7HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919874-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (KY) | 2021-02-16 | — | — | US | disclosed |
| US-20190382370-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2019-12-19 | — | — | US | disclosed |
| US-10370354-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (KY) | 2019-08-06 | — | — | US | disclosed |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2018-08-09 | — | — | US | disclosed |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2018-08-09 | — | — | US | disclosed |
| US-9938255-B2 | Metalloenzyme inhibitor compounds | VPS-3, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2788343-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (NC) INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160214959-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2016-07-28 | — | — | US | disclosed |
| US-9309273-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309273-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2013090210-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-7763734-B2 | Synthesis, structure and use of bisoxazolidines for asymmetric catalysis and synthesis | GEORGETOWN UNIVERSITY (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | GEORGETOWN UNIVERSITY | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190382370-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GAA, GPX1 | CES2 240/4885CES1 152/4885HDAC4 1868/4885 |
| US-10919874-B2 | Metalloenzyme inhibitor compounds | MMEL1, GAA, GPX1 | CES2 240/4885CES1 152/4885HDAC4 1868/4885 |
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | ADH5, ADH1C, ADH1A | CES2 47/4885CES1 161/4885HDAC4 3052/4885 |
| US-10370354-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | CES2 286/4885CES1 198/4885HDAC4 1866/4885 |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CES2 286/4885CES1 198/4885HDAC4 1866/4885 |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CES2 286/4885CES1 198/4885HDAC4 1866/4885 |
| US-20160214959-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CES2 286/4885CES1 198/4885HDAC4 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.